Pyrido(3',2':4,5)thieno(3,2-d)pyrimidine, 4-(4-methyl-1-piperazinyl)-2,7,9-trimethyl- | 165337-66-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: Pyrido(3',2':4,5)thieno(3,2-d)pyrimidine, 4-(4-methyl-1-piperazinyl)-2,7,9-trimethyl-
• 英文别名: 4,11,13-trimethyl-6-(4-methylpiperazin-1-yl)-8-thia-3,5,10-triazatricyclo[7.4.0.02,7]trideca-1(9),2(7),3,5,10,12-hexaene
• CAS: 165337-66-6
• 化学式: C₁₇H₂₁N₅S
• 分子量: 327.453
• InChiKey: HSTHOCUEWWTCHD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  23
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  73.4
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST AND BETA-ADRENERGIC ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE
  申请人：Pharmacia Corporation

  公开号：EP1303306B1

  公开（公告）日：2006-06-21
• Epoxy-steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure
  申请人：Alexander C. John

  公开号：US20050215537A1

  公开（公告）日：2005-09-29

  A combination therapy comprising a therapeutically-effective amount of an epoxy-steroidal aldosterone receptor antagonist and a therapeutically-effective amount of a beta-adrenergic antagonist is described for treatment of circulatory disorders, including cardiovascular disorders such as hypertension, congestive heart failure, cirrhosis and ascites. Preferred beta-adrenergic antagonists are those compounds having high potency and bioavailability. Preferred epoxy-steroidal aldosterone receptor antagonists are 20-spiroxane steroidal compounds characterized by the presence of a 9α,11α-substituted epoxy moiety. A preferred combination therapy includes the beta-adrenergic antagonist metoprolol ((±)1-(isopropylamino)-3-[p-(2-methoxyethyl)phenoxyl]-2-propanolol succinate) and the aldosterone receptor antagonist epoxymexrenone.